Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Glecaprevir and Pibrentasvir in Hepatic Impairment
NCT02296905Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Primary completion
- Sep 2015
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of glecaprevir and pibrentasvir in hepatitis C (HCV) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Overall measurement of pharmacokinetic parameter values of ABT-493 and ABT-530 at 7 days, Overall measurement of safety parameters up to 38 days and 1 more. Started Oct 2014; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02296905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02296905.